The Orange Pill Podcast

In this episode, we dive deep into the Make America Healthy Again (MAHA) Commission’s leaked strategy report, submitted to President Trump earlier this month and quietly leaked before its official release. The “Make Our Children Healthy Again Strategy” lays out sweeping changes to how the federal government addresses childhood chronic disease, from overhauling nutrition guidelines and banning food dyes, to tackling overmedicalizati...

The new EU-US trade deal is here, and it’s sending shockwaves through the dietary supplement industry. While it avoids the 30% tariff originally proposed, the agreement imposes a steep 15% tariff on about 70% of EU exports to the US, up from the previous 1.2%.

In this episode, we break down:

• Who’s Hit Hardest: Why finished dietary supplements aren’t exempt, and what that means for European brands.

• The Ingredient Exception: ...

In this episode, we unpack a major federal push to tackle the diet-related chronic disease crisis in America, with ultra-processed foods (UPFs) in the crosshairs. The U.S. Departments of Health and Human Services and Agriculture, working alongside the FDA and NIH, are launching coordinated initiatives to:

• Define “ultra-processed foods” with a uniform federal standard.

• Fund groundbreaking nutrition research through the new N...

In this episode of the Orange Pill Podcast, we dive into Health Secretary Robert F. Kennedy Jr.’s aggressive push to dismantle the GRAS (“Generally Recognized as Safe”) pathway — a move that’s shaking up both Big Food and the supplement industry.

We explore:

• The origins and exploitation of the GRAS "loophole"
• Why ultraprocessed foods are in the crosshairs
• What this crackdown means for dietary supplements
• Former FDA Commissione...

The FDA is sounding the alarm. In a major regulatory move, the agency is recommending that 7-hydroxymitragynine (7-OH)—a potent synthetic derivative of kratom—be scheduled under the Controlled Substances Act. Why? Because this lab-created version of kratom’s active compound is up to 500% more potent than its natural form and is increasingly tied to severe health risks, including liver toxicity, seizures, substance use disorder, and...

This episode explores Canada’s evolving approach to CBD regulation, focusing on proposed changes that would allow low-dose cannabidiol products to be sold as Natural Health Products without a prescription. It covers the gaps in the current framework under the Cannabis Act, the results of public consultations, and Health Canada’s ongoing efforts to balance safety, access, and industry growth. The discussion also touches on implicati...

Part One of Our Deep Dive into NHP Regulation Reform

Canada’s Natural Health Product (NHP) industry is facing its biggest regulatory shake-up in decades — and we’re here to break it all down. In this must-listen episode, we unpack the newly revised Product Licence Application (PLA) Class system and the controversial cost recovery program introduced by Health Canada.

From how Class I, II, and III applications work, to the major fee ...

This episode explores the surprising benefits of CarnoSyn® beta-alanine beyond sports. A new study reveals that a low, sustained-release dose improved cognitive function and reduced depression scores in older adults with below-average baseline scores—without side effects.

We break down the science behind brain carnosine, its link to BDNF and mood, and what this means for the healthy aging supplement market. Plus, a look at the regu...

In this episode, we unpack the newly introduced Ensuring Safe and Toxic-Free Foods Act of 2025, spearheaded by Senators Markey and Booker. This legislation aims to reform the FDA’s GRAS (Generally Recognized as Safe) system, which has long allowed food companies to self-approve potentially harmful additives without FDA oversight. We explore how this act seeks to phase out self-GRAS determinations, prohibit toxic substances, and dem...

Can magnesium slow brain aging? New research says yes. This episode breaks down emerging evidence on magnesium’s role in preserving brain volume, protecting against white matter lesions, and lowering dementia risk. We explore why post-menopausal women see the strongest benefits, how magnesium regulates neuroinflammation, and what you can do to increase intake through food and supplements.

Find out why magnesium is becoming a key fo...

How do tariffs shape your supplements? In this episode, we break down the economic and regulatory impact of the 2025 Reciprocal Tariff System and Executive Order 14257 on the dietary supplement industry. Learn how key ingredients like CoQ10 and Vitamin B Complex secured tariff exemptions—saving the industry over $200 million in just over two months—and why supplement leaders are pushing back against pharmaceutical-level scrutiny. W...

In this episode of the orange pill podcast, we spotlight a groundbreaking clinical trial that could redefine how  omega-3s are delivered to the brain and eyes. Aker BioMarine has partnered with KGK Science to launch the first-ever human clinical trial on Lysoveta, a next-gen omega-3 ingredient that uses lyso-phosphatidylcholine (LPC) to deliver EPA and DHA across the blood-brain and blood-retina barriers. Why does that matter? Beca...

In this episode of the Orange Pill Podcast, we unpack the FDA’s newly released 2025 Human Foods Programme guidance agenda and the persistent challenges stalling finalization of the long-awaited New Dietary Ingredient (NDI) guidance. From the implications of regulatory orders that demand a "10-for-1" rule, to open questions around bioidentical molecules and the fate of the self-affirmed GRAS pathway, we explore what’s at stake for d...

In this episode of the Orange Pill Podcast, we unpack the federal class action lawsuit alleging deceptive labeling practices on dietary supplements sold through one of the world’s largest online retailers. Plaintiffs claim the company systematically omits mandatory disclaimers and promotes unapproved health claims—leaving consumers under the false impression that the products are FDA-approved.

With the court denying a motion to dis...

A new FDA study reveals that many melatonin supplements—especially those marketed for children—contain wildly inaccurate doses, ranging from 0% to over 600% of what is listed on the label. In this episode, we unpack the science and regulatory implications of this inconsistency. Why is a powerful hormone treated like a harmless vitamin? What does this mean for consumer safety, especially among children? We explore the risks, expert ...

Episode 34 takes a closer look at paraxanthine (Px) — the main metabolite of caffeine — and why it might be the next big thing in clean, functional energy. With claims of fewer jitters, smoother focus, and a safer toxicity profile, Px is drawing attention from both scientists and the beverage industry.

This episode explores:

• How paraxanthine compares to caffeine in terms of safety and effectiveness

• Its nootropic and physica...

Psyllium husk is taking the wellness world by storm, but is it just hype, or a true hero in your supplement stack?

In this episode, we break down what makes psyllium more than just a fiber. From its rising nickname “Nature’s Ozempic” to its documented benefits in digestion, heart health, and even colorectal cancer prevention, we look at where the science stands today.

We also touch on dosage safety, clinical findings, and what form...

In this episode, we explore the findings of a newly published clinical trial investigating the impact of an 84-day probiotic regimen on gut and mental health in older adults aged 50–85 who experience occasional constipation. The probiotic blend—Lactiplantibacillus plantarum strains KABP031 and KABP032 (marketed as INNERIM™)—was tested in a randomized, double-blind, placebo-controlled study to evaluate its efficacy and safety.

The r...

The FDA’s guidelines on when human research studies require an Investigational New Drug (IND) application can be a maze for researchers and sponsors. In this episode, we break it all down for you: from the broad definition of "drugs" under the FD&C Act to exemptions in clinical investigations. We discuss the core criteria that help you determine if your research falls under the IND requirements and how to avoid common pitfall...